BIOMAT Database Logo BIOMAT Database Logo

Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. 1999

R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
West LA VAMC/University of California, Los Angeles, Los Angeles, CA; The Toronto Hospital, Toronto, Ontario, Canada.

High-dose chemotherapy followed by autologous transplantation has been shown to improve response rates and survival in multiple myeloma and other malignancies. However, autografts frequently contain detectable tumor cells. Enrichment for stem cells using anti-CD34 antibodies has been shown to reduce autograft tumor contamination in phase I/II studies. To more definitively assess the safety and efficacy of CD34 selection, a phase III study was completed in 131 multiple myeloma patients randomized to receive an autologous transplant with either CD34-selected or unselected peripheral blood progenitor cells after myeloablative therapy. Tumor contamination in the autografts was assessed by a quantitative polymerase chain reaction detection assay using patient-specific, complementarity-determining region (CDR) Ig gene primers before and after CD34 selection. A median 3.1 log reduction in contaminating tumor cells was achieved in the CD34 selected product using the CEPRATE SC System (CellPro, Inc, Bothell, WA). Successful neutrophil engraftment was achieved in all patients by day 15 and no significant between-arm difference for time to platelet engraftment occurred in patients who received an infused dose of at least 2.0 x 10(6) CD34(+) cells/kg. In conclusion, this phase III trial demonstrates that CD34-selection of peripheral blood progenitor cells significantly reduces tumor cell contamination yet provides safe and rapid hematologic recovery for patients receiving myeloablative therapy.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D006412 Hematopoietic Stem Cells Progenitor cells from which all blood cells derived. They are found primarily in the bone marrow and also in small numbers in the peripheral blood. Colony-Forming Units, Hematopoietic,Progenitor Cells, Hematopoietic,Stem Cells, Hematopoietic,Hematopoietic Progenitor Cells,Cell, Hematopoietic Progenitor,Cell, Hematopoietic Stem,Cells, Hematopoietic Progenitor,Cells, Hematopoietic Stem,Colony Forming Units, Hematopoietic,Colony-Forming Unit, Hematopoietic,Hematopoietic Colony-Forming Unit,Hematopoietic Colony-Forming Units,Hematopoietic Progenitor Cell,Hematopoietic Stem Cell,Progenitor Cell, Hematopoietic,Stem Cell, Hematopoietic,Unit, Hematopoietic Colony-Forming,Units, Hematopoietic Colony-Forming
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
[Autologous peripheral blood selected CD34+ cell transplantation in the treatment of multiple myeloma].
July 2001, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
Autologous peripheral blood progenitor cell transplantation for multiple myeloma.
January 1999, Bailliere's best practice & research. Clinical haematology,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
August 1999, Bone marrow transplantation,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma.
June 1999, Haematologica,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
January 2004, International journal of hematology,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
Haematopoietic reconstitution after autologous transplantation of CD34(+)-selected versus non-selected peripheral blood progenitor cells.
January 1997, Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome.
January 1999, British journal of haematology,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation.
June 2000, Journal of hematotherapy & stem cell research,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
Immunological short term reconstitution after tandem unselected peripheral blood progenitor cell transplantation for multiple myeloma.
July 2000, Haematologica,
R Vescio, and G Schiller, and A K Stewart, and O Ballester, and S Noga, and H Rugo, and C Freytes, and E Stadtmauer, and S Tarantolo, and F Sahebi, and P Stiff, and J Meharchard, and R Schlossman, and R Brown, and H Tully, and M Benyunes, and C Jacobs, and R Berenson, and J DiPersio, and K Anderson, and J Berenson
Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
November 1998, Bone marrow transplantation,
Copied contents to your clipboard!